| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w28071 |
| 来源ID | Working Paper 28071 |
| Internal Deadlines, Drug Approvals, and Safety Problems | |
| Lauren Cohen; Umit Gurun; Danielle Li | |
| 发表日期 | 2020-11-16 |
| 出版年 | 2020 |
| 语种 | 英语 |
| 摘要 | Absent explicit quotas, incentives, reporting, or fiscal year-end motives, drug approvals around the world surge in December, at month-ends, and before respective major national holidays. Drugs approved before these informal deadlines are associated with significantly more adverse effects, including more hospitalizations, life-threatening incidents, and deaths – particularly, drugs most rushed through the approval process. These patterns are consistent with a model in which regulators rush to meet internal production benchmarks associated with salient calendar periods: this “desk-clearing” behavior results in more lax review, leading both to increased output and increased safety issues at particular—and predictable—periodicities over the year. |
| 主题 | Health, Education, and Welfare ; Health ; Other ; Law and Economics ; Development and Growth ; Innovation and R& ; D ; Economic Systems |
| URL | https://www.nber.org/papers/w28071 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/585745 |
| 推荐引用方式 GB/T 7714 | Lauren Cohen,Umit Gurun,Danielle Li. Internal Deadlines, Drug Approvals, and Safety Problems. 2020. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w28071.pdf（3161KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
